BAJAJ BROKING

Notification close image
No new Notification messages
card image
JSW Cement Ltd IPO is Open!
Apply for the JSW Cement Ltd IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Lupin Q1 Results FY25-26: Revenue Up 12% YoY, Net Profit Rises 52%

Lupin Q1 Results FY25-26: Revenue Up 12% YoY, Net Profit Rises 52%

Lupin Limited reported a strong set of results for the first quarter of financial year 2025–26 (Q1 FY26), with solid growth in both revenue and profitability. For the quarter ended June 30, 2025, the company achieved a 12% year-on-year (YoY) increase in revenue, reaching ₹6163.8 crore, while net profit surged by 52% YoY to ₹1219.1 crore. The company's operating margin also improved significantly, highlighting an efficient cost structure and higher contribution from complex generics.

Quick Insights

  • Revenue: ₹6,163.8 crore, up 12% YoY

  • EBITDA: ₹1,641.4 crore, up 27.6% YoY; EBITDA margin rose to 26.6%

  • Net Profit: ₹1,219.1 crore, increased 52.1% YoY

  • As of 6th August, 2025 Lupin share price was ₹1,851.10

  • Gross Profit: ₹4,391.9 crore; margin expanded to 71.3%

  • Other Operating Income: ₹104.5 crore, up 21.6% YoY

LUPIN LIMITED

Trade

1909.557.69 (3.11 %)

Updated - 07 August 2025
1939.90day high
DAY HIGH
1855.00day low
DAY LOW
2735877
VOLUME (BSE)

Sales Breakdown by Geography:

Region

Revenue (₹ crore)

YoY Growth

North America

2,515.5

23%

India

2,089.4

8%

EMEA

626.9

25%

APAC

315.8

3%

LATAM

173.8

17%

RoW

199.3

29%

API

243.1

33%

Quarterly - Lupin Q1 Results FY25-26

The quarter witnessed Lupin’s highest consolidated sales in recent years, backed by sustained performance in the US market, steady growth in India, and a sharp rise in the API and EMEA segments.

Metric

Q1 FY26

Q1 FY25

YoY Growth

Net Sales

₹6,163.8 crore

₹5,514.3 crore

11.8%

EBITDA (excl. Fx)

₹1,641.4 crore

₹1,286.4 crore

27.6%

EBITDA Margin

26.6%

23.3%

+330 bps

Net Profit

₹1,219.1 crore

₹801.3 crore

52.1%

R&D Spend

₹208.6 crore

₹111.7 crore

+86.7%

Capex

₹484.4 crore

₹350.0 crore

+38.4%

Quarter-on-quarter (QoQ), net profit increased by 57.8%, while sales rose 10.8%, indicating strong sequential performance.

Segment Highlights

India Business

  • Revenue: ₹2,089.4 crore, up 8% YoY

  • Rx Sales Growth: 8.6% in line with IPM growth

  • Leading therapeutic areas: Cardiology, Respiratory, Gastrointestinal, and Vitamins-Minerals-Supplements (VMS)

  • Anti-diabetes growth was modest at 6.8% due to loss of exclusivity in key products

  • Launched 5 new products; plans 20+ launches in FY26

  • Chronic therapies contributed ~65% to sales

North America

  • Revenue: ₹2,515.5 crore, up 23% YoY

  • Highest quarterly sales since Q4 FY17

  • Key driver: Launch of Tolvaptan (gJynarque®) with sole 180-day exclusivity

  • Pipeline includes 49 FTFs (19 exclusive), and 100+ new product launches planned till FY30

  • Market share of ~4.5% in US generic prescriptions

API Segment

  • Revenue: ₹243.1 crore, 33% growth YoY

  • Supported internal formulation needs and external sales

  • Certified by TGA (Australia) and WHO Geneva during the quarter

Sector Expectations for Lupin Q1 Results FY25-26

Lupin’s Q1 results outperformed broad sector expectations in terms of margin expansion and profit growth. While many Indian pharma companies faced pricing pressure in the US generics market, Lupin’s performance bucked the trend, aided by exclusive launches and a shift toward complex generics.

R&D and capex investments also aligned well with sectoral strategies, focusing on inhalation, injectables, and biosimilars—high-value areas expected to drive long-term growth.

Management Commentary

The management highlighted consistent improvement in margins driven by operating leverage, product mix optimisation, and strategic launches. Investments in high-complexity products are expected to further enhance profitability and market share.

Compliance improvements were evident:

  • Nagpur Unit-II: Received Establishment Inspection Report (EIR) from US FDA

  • Pithampur Units: Awaiting response review from US FDA after Form 483 issuance

  • Approvals received from global regulators, including WHO, TGA, and HESSEN (Germany)

Source: Q1 FY25-26 Quarterly Results uploaded on 6th August, 2025, on BSE.

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|